The human body produces substances, called endocannabinoids, that work in a similar way to cannabis. These endocannabinoids may not produce a ‘high’, but are of tremendous importance for the functioning of the neural network in the brain, especially during the embryonic stage. If this network is interfered with as a result of too many circulating endocannabinoids, the development of the embryonic brain can be impaired. Researchers at the Medical University of Vienna have now discovered what mechanism underlies the development of this impairment.
The protein Slit and its receptor Robo (roundabout) are important signalling molecules in the developing brain. Slits can regulate directional guidance of nerve cell processes (called axons), by binding to Robo receptors, directing the formation of embryonic brain circuitry. The team have now shown that endocannabinoids can regulate Slit and Robo levels in both nerve cells and oligodendrocytes, which support nerve cells, through cannabinoid receptors CB1 and CB2.
This signalling system is important for correct embryonic brain development. If this system goes haywire due to increased levels of endocannabinoids, a kind of stimulation storm occurs. In this case, both Slit and Robo are produced in greater quantities, leading to changes in axonal guidance decisions. If the endocannabinoid system is in balance, however, this type of over-stimulation does not occur.
The researchers also found this signalling system, and its regulation by cannabinoids, in human embryonic brains. Since, increased endocannabinoid levels are found in metabolic syndromes such as obesity and insulin resistance, as well as during maternal infections, it is important to normalize altered endocannabinoid levels during pregnancy to ensure correct embryonic brain development. The group have demonstrated that the body’s own cannabinoids are able to regulate an important signalling system in the development of embryonic brain circuitry.
Get Healthinnovations delivered to your inbox:
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.